Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06814938
PHASE4
A Study of a Novel Precision Medicine Approach For Obesity
Sponsor: Mayo Clinic
View on ClinicalTrials.gov
Summary
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Official title: A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
135
Start Date
2025-02-21
Completion Date
2028-11
Last Updated
2026-03-02
Healthy Volunteers
No
Conditions
Interventions
DRUG
Semaglutide
2.4 mg subcutaneous weekly
DRUG
Placebo
Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly
Locations (2)
Mayo Clinic in Florida
Jacksonville, Florida, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States